Potential subtype-specific therapeutic approaches in small cell lung cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Potential subtype-specific therapeutic approaches in small cell lung cancer
Authors
Keywords
-
Journal
CURRENT OPINION IN ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-10-22
DOI
10.1097/cco.0000000000001005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer
- (2023) Zsuzsanna Valko et al. BRITISH JOURNAL OF CANCER
- Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
- (2023) Zsolt Megyesfalvi et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
- (2023) Charles M. Rudin et al. Journal of Hematology & Oncology
- De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
- (2023) Subhamoy Chakraborty et al. CLINICAL CANCER RESEARCH
- Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions
- (2023) Chenyue Zhang et al. Journal of Translational Medicine
- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Expression patterns and prognostic relevance of subtype‐specific transcription factors in surgically resected small‐cell lung cancer: an international multicenter study
- (2022) Zsolt Megyesfalvi et al. JOURNAL OF PATHOLOGY
- Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
- (2022) L. Paz-Ares et al. ESMO Open
- Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
- (2021) Carl M. Gay et al. CANCER CELL
- Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
- (2021) Stephen V. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- The landscape of small cell lung cancer metastases: Organ specificity and timing
- (2021) Zsolt Megyesfalvi et al. Thoracic Cancer
- Molecular profiles of small cell lung cancer subtypes: therapeutic implications
- (2021) Anna Schwendenwein et al. Molecular Therapy-Oncolytics
- Small-cell lung cancer in never-smokers
- (2021) M. Torres-Durán et al. ESMO Open
- Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
- (2021) Apar Kishor P. Ganti et al. Journal of the National Comprehensive Cancer Network
- New Approaches to SCLC Therapy: From the Laboratory to the Clinic
- (2020) John T. Poirier et al. Journal of Thoracic Oncology
- Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization
- (2020) Marina K. Baine et al. Journal of Thoracic Oncology
- Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States
- (2020) David A. Siegel et al. JAMA Oncology
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study
- (2019) Daniel Morgensztern et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
- (2019) Taofeek K. Owonikoko et al. Journal of Thoracic Oncology
- POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
- (2018) Yu-Han Huang et al. GENES & DEVELOPMENT
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition
- (2018) Deshui Jia et al. Cancer Discovery
- The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications
- (2018) Wanyin Lim et al. QUANTITATIVE IMAGING IN MEDICINE AND SURGERY
- Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
- (2018) Taofeek K. Owonikoko et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer
- (2014) Neelesh Sharma et al. INVESTIGATIONAL NEW DRUGS
- Selective Tropism of Seneca Valley Virus for Variant Subtype Small Cell Lung Cancer
- (2013) J. T. Poirier et al. JNCI-Journal of the National Cancer Institute
- Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
- (2011) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now